Transtek(SZ:300562) Ge Long Hui·2025-11-07 12:41Core Viewpoint - Lexin Medical (300562.SZ) is undergoing a capital increase and share transfer involving its subsidiary, Shenzhen Xinkang Medical Technology Co., Ltd., to enhance operational efficiency and align with its medium to long-term strategic planning [1][2] Group 1: Capital Increase and Share Transfer - Xinkang Medical plans to raise capital through a share expansion, introducing new shareholder Huize Tiancheng Equity Investment Fund Partnership (Limited Partnership) with an investment of RMB 12 million, of which RMB 2 million will be registered capital and RMB 10 million will be allocated to capital reserves [1] - After the capital increase, Huize Tiancheng will hold 6.25% of Xinkang Medical, while Zhongshan Lexin's shareholding will decrease from 30.00% to 28.125%, and Chaoniu Medical's shareholding will drop from 20.00% to 18.75% [1] - Zhongshan Lexin intends to transfer 18.75% of its shares in Xinkang Medical to individuals Liu Hao and Liao Yunpeng, with each acquiring 9.375% for a price of RMB 3 million [1] Group 2: Shareholder Rights and Decisions - The company has the priority subscription rights for the capital increase and the priority purchase rights for the share transfer as per the Company Law and other relevant regulations [2] - After considering the current operational status and future plans, the company has decided to waive its priority subscription rights and priority purchase rights for this capital increase and share transfer [2]